| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/30/2013 | CN102905725A Marker vaccine for classical swine fever |
| 01/30/2013 | CN102905724A Mycobacterial antigen composition |
| 01/30/2013 | CN102905723A Anti-FGFR2 antibodies |
| 01/30/2013 | CN102905721A Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 01/30/2013 | CN102905709A Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 01/30/2013 | CN102905692A Stable multi-dose compositions comprising antibody and preservative |
| 01/30/2013 | CN102901826A New potential human cytokine TMEM98 and uses thereof |
| 01/30/2013 | CN102899336A Preparation method and application of Coxsackie virus B3 virus-like particles |
| 01/30/2013 | CN102899295A Duck hemorrhagic ovaritis virus |
| 01/30/2013 | CN102899294A Vaccine strain of HIN1 swine influenza virus and application thereof |
| 01/30/2013 | CN102898527A Pharmaceutical composition for preventing or treating cancer |
| 01/30/2013 | CN102898524A Human-mouse chimeric antibody of anti-human tumor necrosis factor related apoptosis-inducing ligand receptor DR5, preparation method and uses thereof |
| 01/30/2013 | CN102898519A Monoclonal antibodies against amyloid beta protein and uses thereof |
| 01/30/2013 | CN102898518A Preparation method for special anti-bovine mastitis pathogenic microorganism IgY |
| 01/30/2013 | CN102895677A Novel multivalent carrier vaccine for shrimp and application thereof |
| 01/30/2013 | CN102895674A Preparation method of chitosan-5'ppp-NS1shRNA nanocomposite |
| 01/30/2013 | CN102895668A Method of delivering a protein into a cell |
| 01/30/2013 | CN102895663A Compositions containing EGFL 7 antagonist for modulating vascular development and methods |
| 01/30/2013 | CN102895660A Bivalent inactivated vaccine for duck virus hepatitis |
| 01/30/2013 | CN102895659A Composite vaccine for Alzheimer's disease prevention and treatment, and preparation method thereof |
| 01/30/2013 | CN102327605B Preparation process of meningococcal polysaccharide vaccine |
| 01/30/2013 | CN102258539B Bee glue injection for preventing duck plague and preparation method thereof |
| 01/30/2013 | CN102172397B In vivo targeting of dendritic cells |
| 01/30/2013 | CN101991844B Edwardsiella tarda recombinant subunit vaccine and application thereof |
| 01/30/2013 | CN101979515B Animal rabies virus and vaccine and production method thereof |
| 01/30/2013 | CN101942013B HLA-DR9 restrictive regulatory T cell epitope of Hepatitis B virus core antigen and e antigen and application thereof |
| 01/30/2013 | CN101914160B Composite of hepatitis B virus core antigen and heat shock protein and preparation method and application thereof |
| 01/30/2013 | CN101721694B Hircine primary atypical pneumonia combined inactivated vaccine and preparation method thereof |
| 01/30/2013 | CN101496897B Vaccine for fish and application |
| 01/30/2013 | CN101397342B Anti-schistosoma japonicum monoclonal antibody NP11-4 chimeric Fab antibody, preparation method and use |
| 01/30/2013 | CN101357944B Anti-idio-typic antibody NP30 chimeric Fab fragment of japonicum, preparation method and application |
| 01/30/2013 | CN101287491B Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica |
| 01/30/2013 | CN101287488B Multiple vaccination including serogroup C meningococcus |
| 01/30/2013 | CN101258166B Antibody combining with STEAP-1 protein and deriving molecule thereof |
| 01/30/2013 | CN101056977B Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection |
| 01/30/2013 | CN101027317B HPV vaccine comprising peptides from host cell proteins |
| 01/29/2013 | US8362217 Purification of biomolecules such as proteins, polypeptides, antibodies and the like by use of a stimuli responsive polymer, such as a solubilized or soluble polymer to capture the desired biomolecules from a solution/suspension by precipitation mechanism and then to further purify them |
| 01/29/2013 | US8362216 Method of detection using antibodies that specifically bind hedgehog-derived polypeptides |
| 01/29/2013 | US8362215 Antibodies immunoreactive with heregulin-coupled HER3 |
| 01/29/2013 | US8362210 Antibody variants with enhanced complement activity |
| 01/29/2013 | US8362208 Immunoglobulins |
| 01/29/2013 | US8361987 DNA vaccines encoding heat shock proteins |
| 01/29/2013 | US8361986 Synthetic agonists of TLR9 |
| 01/29/2013 | US8361978 Use of herpes vectors for tumor therapy |
| 01/29/2013 | US8361933 Polypeptide display libraries and methods of making and using thereof |
| 01/29/2013 | US8361754 Recombinant reverse transcriptases |
| 01/29/2013 | US8361749 Process for preparing variant of Erysipelothrix rhusiopathiae surface protective antigen in E. coli |
| 01/29/2013 | US8361708 Human virus causing severe acute respiratory syndrome (SARS) and uses thereof |
| 01/29/2013 | US8361483 Epinecidin-1 as a vaccine adjuvant for enhancing immune responses |
| 01/29/2013 | US8361482 Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease |
| 01/29/2013 | US8361481 Lactic acid bacterium having anti-allergic activity and pharmaceutical composition |
| 01/29/2013 | US8361480 Attenuated ehrlichiosis vaccine |
| 01/29/2013 | US8361479 Promiscuous PAP CD4 T cell epitopes |
| 01/29/2013 | US8361478 Recombinant viral-based malaria vaccines |
| 01/29/2013 | US8361477 Multiple vaccination including serogroup C Meningococcus |
| 01/29/2013 | US8361476 With a carrier peptide adjuvant that is able to strongly enhance the immune response to a specific co-administered antigen |
| 01/29/2013 | US8361475 ADAM-9 modulators |
| 01/29/2013 | US8361474 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses |
| 01/29/2013 | US8361473 Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
| 01/29/2013 | US8361472 Anti-PSGL-1 antibodies |
| 01/29/2013 | US8361471 Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| 01/29/2013 | US8361470 Methods of treatment using anti-human IL-21 monoclonal antibodies |
| 01/29/2013 | US8361469 Antibodies against tissue factor pathway inhibitor |
| 01/29/2013 | US8361468 Humanized anti-C5aR antibodies |
| 01/29/2013 | US8361467 Antagonist is selected from an antioxidant or an inhibitor of a pro-inflammatory interleukin, TNF- alpha synthesis, membrane-bound TNF- alpha, a natural receptor of TNF- alpha, nitric oxide synthase, phospholipase A2, apoptosis, matrix metalloproteases, or p38 kinase |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361465 Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| 01/29/2013 | US8361464 Anthracycline-Antibody Conjugates for Cancer Therapy |
| 01/29/2013 | US8361463 Humanized antibodies against human interferon-alpha |
| 01/29/2013 | US8361462 Anti-apoptotic protein antibodies |
| 01/29/2013 | US8361461 Anti-IGF-IR antibodies and uses thereof |
| 01/29/2013 | US8361460 Food allergens, method of detecting food allergens and method of detecting food allergy-inducing foods |
| 01/29/2013 | US8361457 Duplexed parvovirus vectors |
| 01/29/2013 | US8361441 Detection and therapy of bacterial infection caused by Enterobacteriaceae |
| 01/29/2013 | CA2522645C New monoclonal antibody capable of binding integrin alpha10beta1 |
| 01/29/2013 | CA2522081C Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
| 01/29/2013 | CA2498315C Cytokine production-inducing antibody |
| 01/29/2013 | CA2467099C Method for the recovery and purification of poxviruses from infected cells |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2416137C Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 01/29/2013 | CA2343929C Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 01/29/2013 | CA2325574C Porcine adenovirus type 3 genome |
| 01/29/2013 | CA2322160C Vaccines, immunotherapeutics and methods for using the same |
| 01/24/2013 | WO2013013179A1 Ruthenium carbon monoxide releasing molecules and uses thereof |
| 01/24/2013 | WO2013013075A2 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 01/24/2013 | WO2013013056A1 Method for treating amyloid disease |
| 01/24/2013 | WO2013013038A2 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 01/24/2013 | WO2013013025A2 Anti-cxcr4 antibodies and methods of use |
| 01/24/2013 | WO2013013013A2 Compositions and methods for producing modified glycoproteins |
| 01/24/2013 | WO2013012947A1 Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas |
| 01/24/2013 | WO2013012894A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| 01/24/2013 | WO2013012875A2 Bacterial rnas as vaccine adjuvants |
| 01/24/2013 | WO2013012855A1 Apelin antigen-binding proteins and uses thereof |
| 01/24/2013 | WO2013012835A2 Sirna useful in the treatment of flavivirus infection |
| 01/24/2013 | WO2013012806A2 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells |
| 01/24/2013 | WO2013012747A1 Rspo binding agents and uses thereof |
| 01/24/2013 | WO2013012743A2 Methods and compositions for inhibiting staphylococcus agglutination in blood |
| 01/24/2013 | WO2013012683A2 Gel vaccine delivery system for treating poultry |
| 01/24/2013 | WO2013012648A1 Gdf15 in diagnostic and therapeutic applications |
| 01/24/2013 | WO2013012457A1 Method of treating and confirming diagnosis of exertional compartment syndrome |